Hims & Hers Health, Inc. (HIMS) Isn’t Regarded As A Great Actor By Doctors, Says Jim Cramer

We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Hims & Hers Health, Inc. (NYSE:HIMS) is one of the stocks Jim Cramer recently discussed.

Hims & Hers Health, Inc. (NYSE:HIMS) is a well-known digital health platform that allows users to order medicines after securing prescriptions. Despite multiple headwinds in 2025, the shares are still up by 93% year-to-date. Hims & Hers Health, Inc. (NYSE:HIMS)’s shares fell by 42% in February after the firm warned that it might be unable to maintain the availability of crucial weight loss drugs on its platform. Then, after the stock gained 61% by late June, it again crashed and lost 35%. This time around, Hims & Hers Health, Inc. (NYSE:HIMS) suffered as weight loss drug maker Novo Nordisk ended its partnership with the firm. As for Cramer, he commented on the firm’s business:

Hims & Hers by the way when you talk to doctors, you talk to people in the business, Hims & Hers is regarded as being a not great actor. I think they’re a good actor for the people.”

Earlier, the CNBC host had discussed short seller sentiment for Hims & Hers Health, Inc. (NYSE:HIMS):

“No matter how much you love these speculative winners, you don’t have a gain until you actually ring the register. At the end of last week, for example, Hims & Hers Health, the online healthcare company, was trading at $64. But then yesterday, the stock fell 22 bucks for an almost 35% decline… What I care about is that this stock… [has] almost tripled in two months. If you owned Hims & Hers up almost 200% and you hadn’t sold any at that point, you were being a knucklehead.

Hims & Hers Health, Inc. (HIMS) Isn't Regarded As A Great Actor By Doctors, Says Jim Cramer

A nurse in a telehealth platform talking with a patient on video call for consultation.

Why? Because this is one of the most heavily shorted stocks in the market. 35% of the shares sold short. A lot of people have been betting against it. The haters are plentiful. In that situation, the stock can erupt on any good news. And there was a lot of good news when HIMS was making money with the Wegovy deal.

But a lot of those gains came on the backs of the short sellers who were forced to cover or buy back the shares they sold short because they couldn’t take the pain. That’s why when a stock goes up that fast and there’s a big short position, you gotta generate some discipline here.”

While we acknowledge the risk and potential of HIMS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than HIMS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.